Search

Your search keyword '"Krucoff, Mitchell"' showing total 1,559 results

Search Constraints

Start Over You searched for: Author "Krucoff, Mitchell" Remove constraint Author: "Krucoff, Mitchell"
1,559 results on '"Krucoff, Mitchell"'

Search Results

4. ACTION-ARC Pediatric and Adult Congenital Heart Disease Ventricular Assist Device Adverse Event Definitions-2023

5. Conversations in cardiology: Late career transitions—Retool, retire, refocus

6. One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease

7. Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial

8. 1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program

9. Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial

10. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention

11. 1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI

12. Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT

13. Minimum Core Data Elements for Transcatheter Mitral Therapies: Scientific Statement by PASSION CV, HVC, and TVTR

14. Sex-stratified differences in early antithrombotic treatment response in patients presenting with ST-segment elevation myocardial infarction

15. Position Statement on Vascular Access Safety for Percutaneous Devices in AMI Complicated by Cardiogenic Shock

16. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index

18. Quantifying patients' preferences on tradeoffs between mortality risk and reduced need for target vessel revascularization for claudication.

19. Minimum Core Data Elements for Evaluation of TAVR: A Scientific Statement by PASSION CV, HVC, and TVT Registry

21. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium

22. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial

23. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy

24. One- Versus Three-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease

25. 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation

26. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI

27. Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction

28. Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program

29. Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies

30. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium

31. Cardiac safety research consortium “shock II” think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock

32. COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial

35. Prehospital crushed versus integral prasugrel loading dose in STEMI patients with a large myocardial area

37. Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock

39. Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease Consensus Definitions From Peripheral Academic Research Consortium (PARC)

40. Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials

42. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry

43. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes

44. Definitions of adverse events associated with extracorporeal membrane oxygenation in children: results of an international Delphi process from the ECMO-CENTRAL ARC

46. The East–West late lumen loss study: Comparison of angiographic late lumen loss between Eastern and Western drug-eluting stent study cohorts

48. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry)

49. The Second Annual Think Tank on Prevention of Sudden Cardiac Death in the Young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium

50. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial

Catalog

Books, media, physical & digital resources